Literature DB >> 33806395

The History and Mystery of Alveolar Epithelial Type II Cells: Focus on Their Physiologic and Pathologic Role in Lung.

Barbara Ruaro1, Francesco Salton1, Luca Braga2, Barbara Wade3, Paola Confalonieri1, Maria Concetta Volpe4, Elisa Baratella5, Serena Maiocchi4, Marco Confalonieri1.   

Abstract

Alveolar type II (ATII) cells are a key structure of the distal lung epithelium, where they exert their innate immune response and serve as progenitors of alveolar type I (ATI) cells, contributing to alveolar epithelial repair and regeneration. In the healthy lung, ATII cells coordinate the host defense mechanisms, not only generating a restrictive alveolar epithelial barrier, but also orchestrating host defense mechanisms and secreting surfactant proteins, which are important in lung protection against pathogen exposure. Moreover, surfactant proteins help to maintain homeostasis in the distal lung and reduce surface tension at the pulmonary air-liquid interface, thereby preventing atelectasis and reducing the work of breathing. ATII cells may also contribute to the fibroproliferative reaction by secreting growth factors and proinflammatory molecules after damage. Indeed, various acute and chronic diseases are associated with intensive inflammation. These include oedema, acute respiratory distress syndrome, fibrosis and numerous interstitial lung diseases, and are characterized by hyperplastic ATII cells which are considered an essential part of the epithelialization process and, consequently, wound healing. The aim of this review is that of revising the physiologic and pathologic role ATII cells play in pulmonary diseases, as, despite what has been learnt in the last few decades of research, the origin, phenotypic regulation and crosstalk of these cells still remain, in part, a mystery.

Entities:  

Keywords:  COVID-19 disease; acute respiratory distress syndrome (ARDS); alveolar type II cells; chronic obstructive pulmonary disease (COPD); epithelial cells; idiopathic pulmonary fibrosis; lung cancer

Mesh:

Substances:

Year:  2021        PMID: 33806395      PMCID: PMC7961977          DOI: 10.3390/ijms22052566

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  88 in total

1.  On the Topological Complexity of Human Alveolar Epithelial Type 1 Cells.

Authors:  Jan Philipp Schneider; Christoph Wrede; Jan Hegermann; Ewald R Weibel; Christian Mühlfeld; Matthias Ochs
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

Review 2.  Clinical trials in acute respiratory distress syndrome: challenges and opportunities.

Authors:  Michael A Matthay; Daniel F McAuley; Lorraine B Ware
Journal:  Lancet Respir Med       Date:  2017-05-26       Impact factor: 30.700

3.  Developmental origin of lung macrophage diversity.

Authors:  Serena Y S Tan; Mark A Krasnow
Journal:  Development       Date:  2016-03-07       Impact factor: 6.868

4.  The type II epithelial cell of the lung. I. Method of isolation.

Authors:  Y Kikkawa; K Yoneda
Journal:  Lab Invest       Date:  1974-01       Impact factor: 5.662

5.  Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells.

Authors:  Ahmad N Nabhan; Douglas G Brownfield; Pehr B Harbury; Mark A Krasnow; Tushar J Desai
Journal:  Science       Date:  2018-02-01       Impact factor: 47.728

Review 6.  The innate immune function of airway epithelial cells in inflammatory lung disease.

Authors:  Pieter S Hiemstra; Paul B McCray; Robert Bals
Journal:  Eur Respir J       Date:  2015-02-19       Impact factor: 16.671

Review 7.  Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease.

Authors:  Chun-zhen Zhao; Xiao-cong Fang; Diane Wang; Fa-di Tang; Xiang-dong Wang
Journal:  Respir Med       Date:  2010-10       Impact factor: 3.415

Review 8.  A review of inflammatory mechanism in airway diseases.

Authors:  Parya Aghasafari; Uduak George; Ramana Pidaparti
Journal:  Inflamm Res       Date:  2018-10-10       Impact factor: 4.575

Review 9.  New Insights into the Immune Molecular Regulation of the Pathogenesis of Acute Respiratory Distress Syndrome.

Authors:  Chin-Yao Yang; Chien-Sheng Chen; Giou-Teng Yiang; Yeung-Leung Cheng; Su-Boon Yong; Meng-Yu Wu; Chia-Jung Li
Journal:  Int J Mol Sci       Date:  2018-02-16       Impact factor: 5.923

10.  Dataset on transcriptional profiles and the developmental characteristics of PDGFRα expressing lung fibroblasts.

Authors:  Mehari Endale; Shawn Ahlfeld; Erik Bao; Xiaoting Chen; Jenna Green; Zach Bess; Matthew Weirauch; Yan Xu; Anne Karina Perl
Journal:  Data Brief       Date:  2017-06-07
View more
  35 in total

Review 1.  Alveolar type II cells and pulmonary surfactant in COVID-19 era.

Authors:  A Calkovska; M Kolomaznik; V Calkovsky
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

2.  P53 mediates the protective effects of metformin in inflamed lung endothelial cells.

Authors:  Khadeja-Tul Kubra; Mohammad A Uddin; Mohammad S Akhter; Antoinette J Leo; Agnieszka Siejka; Nektarios Barabutis
Journal:  Int Immunopharmacol       Date:  2021-11-15       Impact factor: 4.932

3.  WNT Signalling in Lung Physiology and Pathology.

Authors:  Yan Hu; Chiara Ciminieri; Qianjiang Hu; Mareike Lehmann; Melanie Königshoff; Reinoud Gosens
Journal:  Handb Exp Pharmacol       Date:  2021

Review 4.  Regeneration-Associated Transitional State Cells in Pulmonary Fibrosis.

Authors:  Mengxia Shen; Ziqiang Luo; Yan Zhou
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

5.  Severe COVID-19 ARDS Treated by Bronchoalveolar Lavage with Diluted Exogenous Pulmonary Surfactant as Salvage Therapy: In Pursuit of the Holy Grail?

Authors:  Barbara Ruaro; Paola Confalonieri; Riccardo Pozzan; Stefano Tavano; Lucrezia Mondini; Elisa Baratella; Alessandra Pagnin; Selene Lerda; Pietro Geri; Marco Biolo; Marco Confalonieri; Francesco Salton
Journal:  J Clin Med       Date:  2022-06-21       Impact factor: 4.964

6.  Bioinformatics analyses reveal cell-barrier junction modulations in lung epithelial cells on SARS-CoV-2 infection.

Authors:  Mir S Adil; Daulat Khulood; S Priya Narayanan; Payaningal R Somanath
Journal:  Tissue Barriers       Date:  2021-11-05

7.  Elevated serum human epididymis protein 4 is associated with disease severity and worse survival in idiopathic pulmonary fibrosis: a cohort study.

Authors:  Mi Tian; Kaifang Meng; Yujuan Gao; Ji Zhang; Miaomiao Xie; Yaqiong Tian; Xiaoqin Liu; Miao Ma; Ying Cai; Hongyan Wu; Jingjing Ding; Jingyu Chen; Hourong Cai
Journal:  Ann Transl Med       Date:  2022-09

8.  Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis.

Authors:  Elisa Baratella; Barbara Ruaro; Fabiola Giudici; Barbara Wade; Mario Santagiuliana; Francesco Salton; Paola Confalonieri; Michele Simbolo; Aldo Scarpa; Saverio Tollot; Cristina Marrocchio; Maria Assunta Cova; Marco Confalonieri
Journal:  Diagnostics (Basel)       Date:  2021-04-23

Review 9.  The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23

Review 10.  Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome-with a preliminary reference to SARS-CoV-2 pneumonia.

Authors:  Walter Gottlieb Land
Journal:  Genes Immun       Date:  2021-06-17       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.